3 documents found, page 1 of 1
Stratification of ST-Elevation Myocardial Infarction Patients Based on Soluble ...
Napoleão, P; Cabral, L; Selas, M; Freixo, C; Monteiro, MC; Criado, MB; Costa, M; Enguita, F; Viegas-Crespo, AM; Saldanha, C; Mota Carmo, MInvolvement of soluble CD40 ligand (sCD40L) in thrombosis and inflammation on the context of coronary artery disease is currently being revised. In that perspective, we had studied the association of sCD40L with markers of platelet activation and markers of endothelial and vascular function. On that cohort, a stratification of patients with acute myocardial infarction (AMI) 1 month after percutaneous coronary i...
Changes of Soluble CD40 Ligand in the Progression of Acute Myocardial Infarctio...
Napoleão, P; Monteiro, MC; Cabral, L; Criado, MB; Ramos, C; Selas, M; Viegas-Crespo, AM; Saldanha, C; Mota Carmo, M; Cruz Ferreira, R; Pinheiro, TReported in vitro data implicated soluble CD40 ligand (sCD40L) in endothelial dysfunction and angiogenesis. However, whether sCD40L could exert that influence in endothelial dysfunction and angiogenesis after injury in acute myocardial infarction (AMI) patients remains unclear. In the present study, we evaluated the association of sCD40L with markers of platelet activation, endothelial, and vascular function du...
Sinus tissue concentration of moxifloxacin after a single oral dose
Dinis, PB; Monteiro, MC; Martins, ML; Silva, N; Morais, JGMoxifloxacin is a new fluoroquinolone antimicrobial approved for the treatment of acute bacterial rhinosinusitis. In order to assess its distribution pattern into the paranasal sinuses, and specifically to evaluate how the histopathologic changes associated with chronic inflammation affect its tissue penetration, we conducted the present investigation, a randomized, open-label, single dose, sinus-tissue pharmac...